Common adverse reactions The most common adverse reactions (≥20% of patients) listed in the prescribing information include:1 Upper respiratory tract infection Cough Pyrexia (fever) Headache Arthralgia (joint pain) Pain in mouth and throat Serious adverse reactions The serious adverse reactions listed in the prescribing information include:1 Kidney damage was observed in animals who received casimersen. Although kidney toxicity was not observed in the clinical studies with casimersen, kidney damage has been observed after administration of some antisense oligonucleotides Use in a specific population It is not yet known if Amondys 45 (casimersen) affects an unborn baby.1 For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.1 References 1. Full prescribing information [FDA]: Amondys 45 (casimersen) [PDF] Sarepta Therapeutics, Inc., Feb 2021 2. Duchenne muscular dystrophy: the basics Sarepta Therapeutics, last checked on Aug 27, 2020 3. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment Nowak KJ, EMBO Rep. Sep 5, 2004 4. Sarepta Therapeutics Announces FDA Approval of AMONDYS 45 (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45 Sarepta Therapeutics press release, Feb 2021